Simvastatin Use in Patients with Type 2 Diabetes Mellitus: The Effects on Oxidative Stress
Najah R Hadi1, Mohammad A Abdelhussein2, Ammar R M Rudha1
1Department of Pharmacology, Kufa University, Najaf, Iraq.
Objectives:
Studies have shown that people with type 2 diabetes mellitus (T2DM) may develop atherosclerosis due to the disturbance in oxidative control and progressive dyslipidemia. Our study aimed to highlight the benefits of simvastatin treatment in improving serum lipids and reducing oxidative damage in patients with T2DM.
Methods:
Our randomized control trial included 56 patients with T2DM and dyslipidemia. The participants were on glibenclamide (5mg/day) during the period of the study. The patients were divided into two study groups (groups 1 and 2). Group 1 was the control group and consisted of 31 patients. Group 2 consisted of 25 participants, who were given simvastatin 20mg tablet once daily for 12 weeks. The control group did not receive simvastatin. Both groups were followed-up for measurement of blood pressure, pulse rate, serum lipids, and parameters of oxidative stress.
Results:
The simvastatin treated group showed a significant improvement with reduced erythrocyte glutathione compared to the control group (p<0.001). This was also associated with a significant reduction in erythrocyte malondialdehyde in the simvastatin treated group compared to the control group (p<0.001). Serum lipids reflected a similar improvement in the levels of erythrocyte malondialdehyde.
Conclusion:
Our study highlights the beneficial role of simvastatin in improving the degree of oxidative stress in patients with T2DM through its effects on serum lipids and lipid peroxidation.
Insights
Simvastatin treatment significantly reduced oxidative stress and improved serum lipids in patients with type 2 diabetes mellitus (T2DM). This study demonstrates simvastatin
Area of Science:
- Cardiology
- Endocrinology
- Biochemistry
Background:
- Type 2 diabetes mellitus (T2DM) is linked to atherosclerosis, oxidative stress, and dyslipidemia.
- Oxidative control disturbances and dyslipidemia are key factors in T2DM complications.
Purpose of the Study:
- To evaluate the benefits of simvastatin in T2DM patients.
- To assess simvastatin's impact on serum lipids and oxidative damage.
Main Methods:
- A 12-week randomized controlled trial involving 56 T2DM patients with dyslipidemia.
- Participants received either simvastatin (20mg/day) or a placebo, alongside glibenclamide.
- Measurements included blood pressure, pulse rate, serum lipids, and oxidative stress markers.
Main Results:
- Simvastatin significantly reduced erythrocyte glutathione and malondialdehyde (p<0.001).
- Improved serum lipid profiles were observed in the simvastatin group.
- These findings indicate reduced lipid peroxidation and oxidative stress.
Conclusions:
- Simvastatin demonstrates a beneficial role in managing oxidative stress in T2DM.
- The drug improves serum lipids and mitigates lipid peroxidation.
- This highlights simvastatin's potential in T2DM management.
More Related Videos
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Diabetes Mellitus: Type 2 and Gestational
Atherosclerosis III: Management
Psychoneuroimmunology: Diabetes and Cancer
Oral Hypoglycemic Agents: Biguanides and Glitazones
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...


